The researchers reported that tests on animals showed that the monoclonal antibody of a new drug is safe cure possible anthrax poisoning in humans.
Although antibiotics can kill the anthrax bacteria, antibiotics are not effective to kill the poison produced by bacteria.
New drugs, raxibacumab, specific targets of toxicity are now entering the blood vessels. After the anthrax attacks, the patients knew that they were poisoning until the toxin have been exchanged in his veins, and probably very late with antibiotics alone can work effectively, the researchers found.
"These drugs strengthen American defenses against bioterrorism that will work in the face of antibiotic-resistant anthrax bacterium," says principal investigator Sally Bolmer, senior vice president of development and arrangement of the Human Genome Sciences Inc.., The company that developed raxibacumab.
The drug works differently than antibiotics, Bolmer noted. "This is also the action faster than vaccination. Thus, it is a complement to both," he said.
"If we give in time in animals exposed to anthrax or even wait until symptoms develop, we can improve the ability to survive on rabbits and monkeys," he said.
The same dose of drugs given to humans and drugs that can be well tolerated, Bolmer added.
This research report can be viewed online at the New England Journal of Medicine.
In the study, researchers showed that a single dose of raxibacumab an effective treatment for inhalation anthrax in both rabbits and monkeys.
Drugs provide a significant survival advantage for animals that show symptoms. Animals exposed to doses of anthrax approximately 200 times the lethal dose, the researchers said.
In addition, raxibacumab safely given to human volunteers and can be used in the form of clinical disease when life is threatened because of inhalation anthrax, said Bolmer.
Under contract with the U.S. Biomedical Advanced Research and Development Authority, the company has been delivering to the U.S. raxibacumab dose 20.000 Strategic National Stockpile for emergency usage. Approval for the drug from the U.S. Food and Drug Administration is still pending, said Bolmer.
Mingtao Zeng, an assistant professor in the department of microbiology and immunology at the University of Rochester Medical Center, said the study provides solid data to support raxibacumab as candidate drugs for biodefense and public health.
"The most encouraging findings is raxibacumab looks safe and well tolerated, with a high dose on the first phase of human clinical trials, involving 333 healthy volunteers," said Zeng. "I expect that raxibacumab can be used as a prophylactic agent as a short-term protection against anthrax or as a combination drug therapy with antibiotics for a more effective treatment of anthrax."
Dr. Gary Nabel, director of the Vaccine Research Center at the U.S. National Institute of Allergy and Infectious Diseases and is also the author of the companion editorian journal said the study showed that the antibodies can block infection During his animals and similar levels of drug can be given safely to people.
"If there are criteria of satisfaction in animals, a guide regulations used to approve drugs for diseases that can be tested for efficacy in humans," said Nabel.
These antibodies provide new tools for controlling anthrax ifeksi and if proven, will be stocked as a countermeasure against the potential public health threat, "he said.
"The paradigm for approval as a biodefense agents that provide new ways to deal with that threat, although questions remain about how and when to use these drugs and how to provide the stimulus for industry to produce them," said Nabel.
Although antibiotics can kill the anthrax bacteria, antibiotics are not effective to kill the poison produced by bacteria.
New drugs, raxibacumab, specific targets of toxicity are now entering the blood vessels. After the anthrax attacks, the patients knew that they were poisoning until the toxin have been exchanged in his veins, and probably very late with antibiotics alone can work effectively, the researchers found.
"These drugs strengthen American defenses against bioterrorism that will work in the face of antibiotic-resistant anthrax bacterium," says principal investigator Sally Bolmer, senior vice president of development and arrangement of the Human Genome Sciences Inc.., The company that developed raxibacumab.
The drug works differently than antibiotics, Bolmer noted. "This is also the action faster than vaccination. Thus, it is a complement to both," he said.
"If we give in time in animals exposed to anthrax or even wait until symptoms develop, we can improve the ability to survive on rabbits and monkeys," he said.
The same dose of drugs given to humans and drugs that can be well tolerated, Bolmer added.
This research report can be viewed online at the New England Journal of Medicine.
In the study, researchers showed that a single dose of raxibacumab an effective treatment for inhalation anthrax in both rabbits and monkeys.
Drugs provide a significant survival advantage for animals that show symptoms. Animals exposed to doses of anthrax approximately 200 times the lethal dose, the researchers said.
In addition, raxibacumab safely given to human volunteers and can be used in the form of clinical disease when life is threatened because of inhalation anthrax, said Bolmer.
Under contract with the U.S. Biomedical Advanced Research and Development Authority, the company has been delivering to the U.S. raxibacumab dose 20.000 Strategic National Stockpile for emergency usage. Approval for the drug from the U.S. Food and Drug Administration is still pending, said Bolmer.
Mingtao Zeng, an assistant professor in the department of microbiology and immunology at the University of Rochester Medical Center, said the study provides solid data to support raxibacumab as candidate drugs for biodefense and public health.
"The most encouraging findings is raxibacumab looks safe and well tolerated, with a high dose on the first phase of human clinical trials, involving 333 healthy volunteers," said Zeng. "I expect that raxibacumab can be used as a prophylactic agent as a short-term protection against anthrax or as a combination drug therapy with antibiotics for a more effective treatment of anthrax."
Dr. Gary Nabel, director of the Vaccine Research Center at the U.S. National Institute of Allergy and Infectious Diseases and is also the author of the companion editorian journal said the study showed that the antibodies can block infection During his animals and similar levels of drug can be given safely to people.
"If there are criteria of satisfaction in animals, a guide regulations used to approve drugs for diseases that can be tested for efficacy in humans," said Nabel.
These antibodies provide new tools for controlling anthrax ifeksi and if proven, will be stocked as a countermeasure against the potential public health threat, "he said.
"The paradigm for approval as a biodefense agents that provide new ways to deal with that threat, although questions remain about how and when to use these drugs and how to provide the stimulus for industry to produce them," said Nabel.
The standard treatment for anthrax is a 60-day course of an antibiotic, such as Ciprofloxacin(Cipro) or Doxycycline. Which single antibiotic or combination of antibiotics will be most effective for you depends on the type of anthrax you have, your age, overall health and other factors. Treatment is most effective when started as soon as possible
ReplyDelete